15th Jul 2026 14:59
GSK PLC - London-based pharmaceutical company - Completes takeover of Nuvalent Inc, a Boston, Massachusetts-based clinical-stage biopharmaceutical company focused on creating precisely targeted oncology therapies. The total value of the acquisition is about USD10.6 billion. Net of cash acquired, GSK's total investment is about USD9.4 billion. The transaction adds three lung cancer assets to GSK's oncology portfolio, with zidesamtinib and neladalkib "considered potential best-in-class assets", and under Food & Drug Administration review for ROS1-positive and ALK-altered non-small cell lung cancer. GSK says: "Both have received FDA breakthrough therapy and orphan drug designations. If approved, they are expected to launch in 2026 with multi-blockbuster potential."
GSK Chief Executive Officer Luke Miels says: "Today's deal completion accelerates our entry into lung cancer with zidesamtinib and neladalkib and a platform for rapid expansion with Ris-Rez, our B7-H3 targeted antibody drug conjugate in phase III development. There is a clear need for these medicines in defined patient populations, consistent with our approach of acquiring validated assets that aim to improve standard of care."
Current stock price: 1,914.00 pence each, down 0.3% on Wednesday afternoon in London
12-month change: up 36%
By Tom Budszus, Alliance News slot editor
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Glaxosmithkline